Waters Corporation Expands Portfolio with Acquisition of Halo Labs

In a strategic move to enhance its capabilities in the biopharmaceutical analytical space, Waters Corporation, a leader in analytical instruments and technologies, has announced the acquisition of Halo Labs. Halo Labs specializes in advanced imaging technologies for the detection and analysis of particulates in therapeutic products. The acquisition will integrate Halo Labs' Aura technology, known for its comprehensive particle analysis, with Waters' existing portfolio, notably its light scattering detection solutions from Wyatt Technology. This merger will broaden Waters' capabilities, particularly in analyzing particle impurities in large molecule therapies such as CAR-T cell therapies. The high throughput, low sample volume technology of Halo Labs represents a significant advancement in obtaining early-stage insights into therapeutic development and manufacturing. Waters' CEO, Dr. Udit Batra, emphasized the importance of this acquisition in maintaining leadership in specialized analytical technologies for emerging biopharmaceutical therapies. Rick Gordon, CEO of Halo Labs, echoed this sentiment, highlighting the shared vision of innovation and commitment to drug safety. Although the acquisition is not expected to significantly impact Waters' financial results within the next year, it positions the company strongly for future growth in the analytical testing and bioprocessing sectors.